Match Document Document Title
US20110097400 MAGNESIUM SYSTEM AND USE THEREOF IN THE COSMETICS INDUSTRY  
A magnesium-based system suitable for use in skincare comprises (a) a first magnesium source in the form of a progressive-release oral tablet exhibiting in vitro, after 2 h in 0.1N HCl medium, a...
US20120258173 Functionally-Coated Multilayer Tablets  
Multilayer functionally coated tablets for oral administration of one or more active pharmaceutical ingredients containing one or more quick release layers and one or more modified release layers...
US20120128771 TIMED, PULSATILE RELEASE SYSTEMS  
A unit multiparticulate dosage form for delivering one or more basic, active pharmaceutical ingredients into the body in need of such medications to achieve target PK (pharmacokinetics) profiles...
US20120015031 NOVEL GASTRO-RETENTIVE DOSAGE FORMS  
A gastro-retentive pharmaceutical dosage form comprising a therapeutically effective amount of at least one opioid, at least one form of acetaminophen, optionally an opioid antagonist and at least...
US20110268799 ORAL CONTROLLED RELEASE DOSAGE FORM  
A dosage form that provides a controlled release solid dosage form for the oral administration of a central nervous system stimulant, preferably methylphenidate hydrochloride.
US20150231131 ONCE-A-DAY OXYCODONE FORMULATIONS  
The invention is directed to sustained release formulations containing oxycodone or a pharmaceutically acceptable salt thereof which provide a mean C24/Cmax oxycodone ratio of 0.6 to 1.0 or 0.7 to...
US20150140095 ONCE-A-DAY OXYCODONE FORMULATIONS  
The invention is directed to sustained release formulations containing oxycodone or a pharmaceutically acceptable salt thereof which provide a mean C24/Cmax oxycodone ratio of 0.6 to 1.0 or 0.7 to...
US20140377349 CONTROLLED RELEASE ORAL DOSAGE FORM COMPRISING OXYCODONE  
The present invention relates to a controlled-release oral dosage form for administration of oxycodone once a day and a method of preparing a controlled-release oral dosage form for administration...
US20120244218 Calcium supplement  
An oral dosage form for administration to an animal comprising a biologically utilizable form of calcium and a extended release system that maintains the calcium level in the animal's bloodstream...
US20110177167 Hydrophilic/Lipophilic Polymeric Matrix Dosage Formulation  
An oral dosage form comprising a pharmaceutical tablet of one or more layers, one of which carries a biologically active substance; the formulation of said tablet includes different percentages of...
US20140271852 SUSTAINED RELEASE FORMULATION OF NALBUPHINE  
Sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof; methods for making the sustained release formulations of nalbuphine or pharmaceutically acceptable salts...
US20110274751 TRIMETAZIDINE FORMULATION WITH DIFFERENT RELEASE PROFILES  
A multilayered solid oral pharmaceutical formulation of trimetazidine or a pharmaceutically acceptable salt or polymorph of trimetazidine wherein one layer of said formulation provides controlled...
US20130273156 ORAL PHARMACEUTICAL TABLET FOR CONTROLLED RELEASE OF MESALAZINE AND PROCESS FOR OBTAINING IT  
The invention provides an oral pharmaceutical tablet for controlled release of mesalazine or a pharmaceutically acceptable salt thereof as active ingredient with a core and a gastro-resistant...
US20140302137 FORMULATION FOR CO-THERAPY TREATMENT OF DIABETES  
The present invention is directed a pharmaceutical compositions for co-therapy treatment and prevention of glucose-related disorders such as Type 2 diabetes mellitus and Syndrome X.
US20120009259 FORMULATION FOR CO-THERAPY TREATMENT OF DIABETES  
The present invention is directed a pharmaceutical compositions for co-therapy treatment and prevention of glucose-related disorders such as Type 2 diabetes mellitus and Syndrome X.
US20110159095 TREATMENT OF ADRENAL INSUFFICIENCY  
The disclosure relates to a pharmaceutical formulation, for example a tablet, adapted for delayed and sustained release of hydrocortisone and a treatment regime that uses said tablet in the...
US20140370086 SUBLINGUAL IMMUNOTHERAPY WITH REDUCED ORAL ITCHINESS  
Sublingual immunotherapy (SLIT) with reduced oral itchiness is disclosed. The improved sublingual immunotherapy combines a monotonically increasing dose of allergen, along with a constant dose of...
US20120201889 MODIFIED AND IMMEDIATE RELEASE FORMULATIONS OF MEMANTINE  
The present invention provides immediate release and modified release oral dosage forms. Specifically, the invention provides modified and immediate release pharmaceutical dosage forms containing...
US20150164806 LAYERED PHARMACEUTICAL FORMULATIONS  
In one embodiment a layered pharmaceutical formulation includes two or more pharmaceutical layers and an intermediate layer disposed between at least two of the two or more pharmaceutical layers,...
US20110008431 THERAPEUTIC TABLET FOR POSTHERPETIC NEURALGIA AND METHOD OF TREATING POSTHERPETIC NEURALGIA  
The present invention provides a tablet for treating postherpetic neuralgia and a method of treating postherpetic neuralgia with the use of the tablet. The therapeutic tablet for postherpetic...
US20130287846 ABUSE-PROOFED ORAL DOSAGE FORM  
The present invention relates to an abuse-proofed oral dosage form with controlled release of (1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol for once daily administration, which...
US20140072626 ONCE DAILY FORMULATIONS OF TETRACYCLINES  
Disclosed are once-daily formulations containing tetracyclines, especially doxycycline. Such formulations are useful, for instance, for the treatment of collagenase destructive enzyme-dependent...
US20150238418 CONTROLLED RELEASE HYDROCODONE FORMULATIONS  
A solid oral controlled-release dosage form of hydrocodone is disclosed, the dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof,...
US20130302418 CONTROLLED RELEASE HYDROCODONE FORMULATIONS  
A solid oral controlled-release dosage form of hydrocodone is disclosed, the dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof,...
US20140186439 STABLE COMPOSITIONS OF FAMOTIDINE AND IBUPROFEN  
Stable pharmaceutical compositions of famotidine and ibuprofen in a single unit dosage form are disclosed herein. The compositions comprise a famotidine core having a reduced or minimal surface...
US20140302141 Triple Combination Release Multi-layered Tablet  
This invention pertains to a multi-layered tablet for a triple combination release of active agents to an environment of use. More particularly, the invention pertains to a multi-layered tablet...
US20130295177 CONTROLLED RELEASE HYDROCODONE  
A solid oral controlled-release dosage form of hydrocodone is disclosed, the dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof,...
US20130266651 LONG ACTING DUAL RELEASE PRODUCT CONTAINING CARBINOXAMINE AND PSEUDOEPHEDRINE  
Provided are oral dosage forms that contain carbinoxamine in an immediate release format, and pseudoephedrine in a prolonged release format. The biphasic oral dosage forms may also contain other...
US20150104506 ORALLY AVAILABLE PHARMACEUTICAL FORMULATION SUITABLE FOR IMPROVED MANAGEMENT OF MOVEMENT DISORDERS  
The present invention provides a pharmaceutical formulation for oral administration comprising an agonist of two or more of the 5-HT1B, 5-HT1D and 5-HT1F receptors, such as a triptan, e.g....
US20130317038 METHOD OF TREATING ATRIAL FIBRILLATION  
The present invention relates to a method for the treatment or prevention of atrial fibrillation and/or atrial flutter comprising coadministration of a synergistically therapeutic amount of...
US20120276201 COMPOSITIONS AND METHOD FOR TREATMENT AND PROPHYLAXIS OF INFLAMMATORY BOWEL DISEASE  
Methods and compositions for treating inflammatory bowel disease involve the use of targeted antibiotics in combination with probiotic formulations. The probiotics mitigate many of the deleterious...
US20150030677 Tamper Resistant Immediate Release Formulations  
Disclosed is an immediate release solid oral dosage form comprising (i) an active agent; and (ii) a material that is sensitive to acidic pH;
US20150209375 POSOLOGY AND ADMINISTRATION OF GLUCOCORTICOID BASED COMPOSITIONS  
The present invention relates to an improved method of administration of glucocorticoid based composition in glucocorticoid replacement therapies enabling an objectively based regimen for...
US20110052689 SUSTAINED RELEASE OF GUAIFENESIN  
The invention relates to a novel pharmaceutical sustained release formulation of guaifenesin. The formulation may comprise a hydrophilic polymer, preferably a hydroxypropyl methylcellulose, and a...
US20150037413 TAMPER RESISTANT DOSAGE FORMS  
The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of...
US20150037412 TAMPER RESISTANT DOSAGE FORMS  
The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of...
US20150037411 TAMPER RESISTANT DOSAGE FORMS  
The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of...
US20140030327 TAMPER RESISTANT DOSAGE FORMS  
The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of...
US20130259940 TAMPER RESISTANT DOSAGE FORMS  
The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of...
US20130259939 TAMPER RESISTANT DOSAGE FORMS  
The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of...
US20130259938 TAMPER RESISTANT DOSAGE FORMS  
The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of...
US20130251802 TAMPER RESISTANT DOSAGE FORMS  
The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of...
US20130251801 TAMPER RESISTANT DOSAGE FORMS  
The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of...
US20130251800 TAMPER RESISTANT DOSAGE FORMS  
The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of...
US20130251799 TAMPER RESISTANT DOSAGE FORMS  
The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of...
US20130251798 TAMPER RESISTANT DOSAGE FORMS  
The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of...
US20150250733 ORAL DRUG DELIVERY FORMULATIONS  
In an aspect, a formulation is provided that comprises at least one active substance and at least one coat comprising Eudragit E (dimethylaminoethyl methacrylate copolymer), wherein the...
US20150164920 CONTROLLED RELEASE FORMULATION COMPRISING MESALAMINE  
The present invention refers to a controlled release pharmaceutical formulation in solid form comprising Mesalamine. The invention also contemplates the preparation of the said formulation and its...
US20140308346 COMBINATION THERAPY FOR EFFECTING WEIGHT LOSS AND TREATING OBESITY  
The present invention features a novel therapy for effecting weight loss which involves treating a subject with a sympathomimetic agent (e.g., phentermine or a phentermine-like drug) in...
US20110217371 CONTROLLED-RELEASE MICROPARTICLES AND METHOD OF PREPARING SAME  
Disclosed is a controlled-release microparticle: including a matrix comprising a pharmacologically active component; and a controlled-release layer comprising a substance which forms a...